Zenas BioPharma (NASDAQ:ZBIO) Trading 9.3% Higher – Here’s Why

01 Jul 2026, 18:21 by Mitch Edgeman · The Markets Daily

Zenas BioPharma, Inc. (NASDAQ:ZBIO – Get Free Report) shares traded up 9.3% on Wednesday . The company traded as high as $27.48 and last traded at $27.7450. Approximately 921,229 shares traded hands during mid-day trading, an increase of 9% from the average daily volume of 845,281 shares. The stock had previously closed at $25.38.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Wednesday, June 24th. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Morgan Stanley boosted their target price on Zenas BioPharma from $21.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.29.

Get Our Latest Stock Analysis on ZBIO

Zenas BioPharma Stock Up 13.5%

The stock has a market cap of $1.82 billion, a PE ratio of -3.40 and a beta of -0.71. The company has a debt-to-equity ratio of 1.04, a current ratio of 11.94 and a quick ratio of 11.94. The company has a 50 day moving average price of $19.48 and a two-hundred day moving average price of $23.15.

Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same quarter in the prior year, the firm earned ($0.80) EPS. Analysts expect that Zenas BioPharma, Inc. will post -4.47 EPS for the current year.

Insider Activity

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. purchased 60,000 shares of Zenas BioPharma stock in a transaction dated Monday, May 18th. The shares were acquired at an average price of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the transaction, the chief executive officer owned 96,928 shares of the company’s stock, valued at $1,636,144.64. This trade represents a 162.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have bought a total of 120,000 shares of company stock worth $2,080,000 over the last 90 days. 22.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zenas BioPharma

Several large investors have recently added to or reduced their stakes in the business. Quarry LP increased its holdings in Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares during the period. Deutsche Bank AG increased its holdings in Zenas BioPharma by 4.5% in the fourth quarter. Deutsche Bank AG now owns 12,781 shares of the company’s stock valued at $464,000 after buying an additional 554 shares in the last quarter. CWM LLC raised its position in shares of Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after buying an additional 709 shares during the last quarter. Two Sigma Investments LP raised its holdings in Zenas BioPharma by 3.9% in the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock valued at $452,000 after acquiring an additional 765 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Zenas BioPharma by 5.8% during the 3rd quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after purchasing an additional 818 shares during the period.

About Zenas BioPharma

(Get Free Report)

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.